The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary ...

German pharmaceutical giant Merck has completed a €3 billion ($3. 5 billion) takeover of US biopharmaceutical company ...

A little over two months after it was announced, Germany-based life sciences firm Merck KGaA said Tuesday that it has ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 ...

Merck (NSE: PROR) KGaA, Darmstadt, Germany, has completed its acquisition of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a company with strong financial fundamentals and impressive revenue ...

After months of discussion, Germany’s Merck KGaA said Monday it would buy SpringWorks Therapeutics for $47 a share in cash, a deal with an equity value of nearly $4 billion. The acquisition was ...

Summary. Merck KGaA agreed to acquire SpringWorks Therapeutics for $47 per share in cash or for $3.9 billion; the acquisition brings in drugs of OGSIVEO and GOMEKLI to big pharma's pipeline.

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said.. An announcement may come as soon as Monday, the people said, asking not to be ...

Merck (NSE: PROR) KGaA, Darmstadt, Germany, has completed its acquisition of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a company with strong financial fundamentals and impressive revenue growth ...

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business Provided by GlobeNewswire Apr 28, 2025, 6:13:33 AM ...